Together, these findings indicate that MAP1B is a robust effector of UBQLN2 ALS mutations in HeLa and LCL cells and that the changes in MAP1B protein abundance are most likely driven by an increase at the level of MAP1B transcript. The gene discussed is MAP1B; the disease is amyotrophic lateral sclerosis.